+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 56 Pages
  • April 2023
  • GlobalData
  • Genmab AS
  • ID: 1291999
Genmab AS (GMAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Genmab AS (Genmab) is a biotechnology company that develops differentiated human antibody therapies for the treatment of cancer and other diseases. The company's marketed antibodies include ofatumumab (Kesimpta) for the treatment of relapsing multiple sclerosis, daratumumab (Darzalex) for the treatment of AL amyloidosis and multiple myeloma, and teprotumumab (Tepezza) for thyroid eye disease. Its products are based on proprietary antibody technologies, namely, HexaBody, DuoBody, DuoHexaBody, and HexElect technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, Japan and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS Key Recent Developments

  • Apr 18, 2023: Genmab announces net sales of DARZALEX (daratumumab) for first quarter of 2023
  • Mar 28, 2023: Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer
  • Feb 23, 2023: Notice to Convene the Annual General Meeting of Genmab A/S
  • Feb 22, 2023: Genmab Publishes 2022 Annual Report

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • Genmab AS - Key Facts
  • Genmab AS - Key Employees
  • Genmab AS - Key Employee Biographies
  • Genmab AS - Major Products and Services
  • Genmab AS - History
  • Genmab AS - Company Statement
  • Genmab AS - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Genmab AS - Business Description
  • Product Category: Collaboration revenue
  • Performance
  • Product Category: License Revenue
  • Performance
  • Product Category: Milestone Revenue
  • Performance
  • Product Category: Reimbursement Revenue
  • Performance
  • Product Category: Royalties
  • Performance
  • R&D Overview
  • Genmab AS - Corporate Strategy
  • Genmab AS - SWOT Analysis
  • SWOT Analysis - Overview
  • Genmab AS - Strengths
  • Genmab AS - Weaknesses
  • Genmab AS - Opportunities
  • Genmab AS - Threats
  • Genmab AS - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Genmab AS, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Apr 18, 2023: Genmab announces net sales of DARZALEX (daratumumab) for first quarter of 2023
  • Mar 28, 2023: Genmab Announces Appointment of Martine van Vugt to Chief Strategy Officer
  • Feb 23, 2023: Notice to Convene the Annual General Meeting of Genmab A/S
  • Feb 22, 2023: Genmab Publishes 2022 Annual Report
  • Feb 22, 2023: Genmab Files Annual Report with the U.S. Securities and Exchange Commission
  • Jan 24, 2023: Genmab announces net sales of DARZALEX (daratumumab) for 2022
  • Dec 12, 2022: Genmab to hold 2022 R&D update and ASH Data Review Meeting
  • Nov 09, 2022: Genmab Announces Financial Results for the First Nine Months of 2022
  • Aug 10, 2022: Genmab Announces Financial Results for the First Half of 2022
  • Jul 19, 2022: Genmab Announces Net Sales of DARZALEX for the Second Quarter of 2022
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Genmab AS, Key Facts
  • Genmab AS, Key Employees
  • Genmab AS, Key Employee Biographies
  • Genmab AS, Major Products and Services
  • Genmab AS, History
  • Genmab AS, Other Locations
  • Genmab AS, Subsidiaries
  • Genmab AS, Key Competitors
  • Genmab AS, Ratios based on current share price
  • Genmab AS, Annual Ratios
  • Genmab AS, Interim Ratios
  • Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Genmab AS, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • Genmab AS, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Genmab AS, Performance Chart (2018 - 2022)
  • Genmab AS, Ratio Charts
  • Genmab AS, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • Genmab AS, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Amgen Inc
  • Genentech USA Inc
  • Agenus Inc
  • Merus NV
  • Teva Pharmaceutical Industries Ltd
  • Merck KGaA
  • Takeda Pharmaceutical Co Ltd
  • Biogen Inc
  • Regeneron Pharmaceuticals Inc
  • Bayer AG
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Merus NV
  • Agenus Inc
  • Genentech USA Inc
  • Takeda Pharmaceutical Co Ltd
  • Merck KGaA
  • Amgen Inc
  • Regeneron Pharmaceuticals Inc
  • Biogen Inc
  • Sanofi
  • Bayer AG